Mavefund EN
Phio Pharmaceuticals Corp logo

Phio Pharmaceuticals Corp

PHIO
Letzter Kurs (USD) US$1.13
Marktkapitalisierung (USD) US$13.1m
Kursänderung 12 Monate -42.93%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Halozyme Therapeutics IncHALO Vergleich Corcept Therapeutics IncorporatedCORT Vergleich Exelixis IncEXEL Vergleich Zoetis IncZTS Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Phio Pharmaceuticals Corp Überblick

Branche: Biotechnology

Sektor: Healthcare

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy; PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in T and tumor cells; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy; PH-894 that silences the epigenetic protein B

Research-Überblick

Letztes Berichtsdatum 2026-08-06

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Phio Pharmaceuticals Corp (PHIO): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
PHIO · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Biotechnology
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-06
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Phio Pharmaceuticals Corp für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 06, 2026

Quarterly result summary

Net loss was -$4.1M (from $2.2M). Cash was $13M.

Net loss -$4.1M from $2.2M
Cash $13M reported

Was sich verändert hat

  • Net loss was -$4.1M (from $2.2M).

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing FORM 8-K Aug 06, 2026 SEC filing FORM 10-Q Aug 06, 2026 SEC filing FORM 10-Q May 07, 2026 SEC filing FORM 8-K May 07, 2026 Earnings release EXHIBIT 99.1 May 07, 2026 SEC filing FORM 10-K Mar 05, 2026 SEC filing FORM 8-K Mar 05, 2026 Earnings release EXHIBIT 99.1 Mar 05, 2026 SEC filing FORM 10-Q Nov 13, 2025 SEC filing FORM 8-K Nov 13, 2025 Earnings release EXHIBIT 99.1 Nov 13, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 2.00/5
Phio Pharmaceuticals Corp earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Eigenkapitalrendite

Score 0.60/5
Phio Pharmaceuticals Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Phio Pharmac... PHIO US$13.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 1.04/5
Phio Pharmaceuticals Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Phio Pharmac... PHIO US$13.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

Verschuldung

Score 3.38/5
Phio Pharmaceuticals Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Phio Pharmac... PHIO US$13.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Phio Pharmaceuticals Corp logo

Phio Pharmaceuticals Corp

US$1.13

US$13.1m

-4.32%

-42.93%